Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465296 · ClinicalTrials.gov registry record · Phase 3
Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS
A Phase 3 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00465296 is a Phase 3 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 200 participants.
The verdict
NCT00465296, a Phase 3 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The primary objective of this clinical trial is to assess the efficacy of rosiglitazone on bare metal stent (BMS) in-stent restenosis measured as late lumen loss in patients with metabolic syndrome. The secondary parameter for evaluation of efficacy is binary restenosis. The tertiary objective will be to assess the effect of rosiglitazone on major cardiac events (MACE; death, MI, CABG, and target vessel revascularization). The occurrence of in-stent restenosis for patients with metabolic syndrome who receive a DES in a non-target lesion will be assessed angiographically at 9 months.
Interventions
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465296
The ClinicalTrials.gov registry entry for NCT00465296 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone is the first listed.
NCT00465296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465296 about?
NCT00465296 is a clinical study titled "Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS". The primary objective of this clinical trial is to assess the efficacy of rosiglitazone on bare metal stent (BMS) in-stent restenosis measured as late lumen loss in patients with metabolic syndrome. The secondary parameter for evaluation of efficacy is binary restenosis. The tertiary objective wil...
What is the current status of trial NCT00465296?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2006-01. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00465296?
The interventions under investigation include: rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00465296?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.